Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

13.0K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
13.0K
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

648
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
648
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

694
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
694
Drug Binding to Blood Components01:30

Drug Binding to Blood Components

667
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
667
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

795
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
795

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thioredoxin Reductase as a Target for Antibacterial Gold Compounds in Burkholderia cenocepacia: Disclosing the Molecular Basis of Enzyme Inhibition.

Chembiochem : a European journal of chemical biology·2026
Same author

Tuning Au Reactivity Beyond Canonical Targets: Ligand-Driven Au(I) Metalation of Lysine Residues in Hen Egg White Lysozyme.

Inorganic chemistry·2026
Same author

Gold-containing compounds target an apicomplexan Thioredoxin reductase: Disclosing reactivity through structural and functional characterization.

International journal of biological macromolecules·2026
Same author

Di-His-Cu(II)-NTA spin labels for probing protein dynamics: Support from a combined crystallographic/EPR study.

Structure (London, England : 1993)·2026
Same author

Binding of Aqueous-Stable, Lipophilic, Hemocompatible Anticancer V<sup>V</sup>O<sub>2</sub> Metallodrugs with Biological Molecules: X-ray Structures of the Adduct of the V<sup>V</sup>-hydrazonato Complex with Hen Egg White Lysozyme.

Inorganic chemistry·2026
Same author

Ru and Rh binding sites in the structure of human serum transferrin with Fe<sup>3+</sup> bound at the C-lobe.

Dalton transactions (Cambridge, England : 2003)·2026

Related Experiment Video

Updated: Apr 14, 2026

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
08:34

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

10.7K

Cisplatin binding to human serum albumin: a structural study.

Giarita Ferraro1, Lara Massai, Luigi Messori

  • 1Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario di Monte Sant'Angelo, Via Cintia, I-80126, Napoli, Italy. antonello.merlino@unina.it.

Chemical Communications (Cambridge, England)
|April 16, 2015
PubMed
Summary

Cisplatin, a cancer drug, binds to human serum albumin (HSA) primarily at His105 and Met329. This study reveals the first crystal structures of this cisplatin/HSA adduct, detailing multiple binding sites.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.1K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.6K

Related Experiment Videos

Last Updated: Apr 14, 2026

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
08:34

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

10.7K
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.1K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.6K

Area of Science:

  • Biochemistry
  • Structural Biology
  • Pharmacology

Background:

  • Cisplatin is a widely used platinum-based chemotherapy drug.
  • Human serum albumin (HSA) is the most abundant protein in human plasma.
  • Understanding drug-protein interactions is crucial for drug development and efficacy.

Purpose of the Study:

  • To elucidate the binding interactions between cisplatin and human serum albumin (HSA).
  • To determine the precise locations of cisplatin binding on the HSA molecule at the atomic level.

Main Methods:

  • X-ray crystallography was employed to investigate the reaction.
  • Crystal structures of the cisplatin/HSA adduct were solved.

Main Results:

  • The crystal structures provide unambiguous evidence of cisplatin binding.
  • Cisplatin predominantly binds to His105 and Met329 side chains of HSA.
  • Additional binding sites were identified at His288, Met298, Met548, His535, His67, and His247.

Conclusions:

  • The study provides the first structural insights into cisplatin-HSA adduct formation.
  • Detailed binding site information can inform the design of improved platinum-based drugs.
  • Understanding these interactions may help predict or mitigate cisplatin toxicity.